Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Reconstituted BPC-157 typically remains viable for several weeks when stored consistently under refrigeration, though the exact window depends on the specific vial and manufacturer guidance
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
a shift toward fat storage in adipose tissue
Swirl gently, do not shake
(Provides pharmacological details on pyridoxine, including its role as a coenzyme in neurotransmitter synthesis and interactions such as the antagonism of levodopa and reduction of phenytoin levels)
Gut Health: More research must be accomplished, but BPC-157 has the potential to restore gut lining and aid a user with debilitating illnesses such as Crohn's disease or stomach ulcers
